Table 1.

Global liver cancer treatment outcomes: results of the GIDEON study

	n	MST, months (95%CI)
Japan	500	79.6 (62.1–96.0)
European Union	1115	25.0 (22.9–28.7)
Asia Pacific	955	20.9 (17.3–25.2)
South America	90	19.5 (13.5–NE)
North America	553	14.8 (13.1–17.0)

MST = median survival time; CI = confidence interval; NE = Not, evaluable. Reproduced with permission from Kudo M, et al. [53].